Novel therapeutic agents for relapsed classical Hodgkin lymphoma
- 11 December 2018
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 184 (1) , 105-112
Abstract
Summary: Hodgkin Lymphoma (HL) is a B‐cell lymphoproliferative disorder with an excellent prognosis for the majority of patients who are treated with multi‐agent chemotherapy, with or without radiation. A subset of patient, however, does not respond to therapy or relapses after accomplishing an initial response. Their outcome is poor and new treatment strategies are urgently needed for this patient population. Recent advances in the understanding of the tumour biology of HL and its microenvironment have ushered a new era of targeted‐ and immuno‐therapies with remarkable activity. Most notably, the antibody‐drug conjugate brentuximab‐vedotin, and the immune checkpoint blockers pembrolizumab and nivolumab have recently been approved by the US Food and Drug Administration and have transformed the therapeutic landscape of this disease. Other novel drug compounds are being investigated either as single agents or in combination and hold promise to further the field.Keywords
This publication has 59 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2011
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2009
- Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2008
- Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experienceHaematologica, 2008
- Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative ProtocolTransplantation and Cellular Therapy, 2006